Emerging treatment for chronic migraine and refractory chronic migraine

Expert Opinion on Emerging Drugs

Volumn 17, Issue 3, 2012, Pages 393-406

  Lionetto, Luana ^a   Negro, Andrea ^a,c   Palmisani, Stefano ^b   Gentile, Giovanna ^a   Fiore, Maria Rosaria Del ^a   Mercieri, Marco ^a   Simmaco, Maurizio ^a   Smith, Thomas ^b   Al Kaisy, Adnan ^b   Arcioni, Roberto ^a   Martelletti, Paolo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antiepileptic drugs; Chronic migraine; Neuromodulation; OnabotulinumtoxinA; Refractory chronic migraine

Indexed keywords

AMITRIPTYLINE; AMPA RECEPTOR ANTAGONIST; ANALGESIC AGENT; ANTICONVULSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BGG 492; BMS 927711; BOTULINUM TOXIN A; BROMOLYSERGIDE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CARBON DIOXIDE; ETIRACETAM; HARKOSERIDE; LASMIDITAN; LLL 2011; MK 6096; NONSTEROID ANTIINFLAMMATORY AGENT; NXN 188; PLACEBO; PROPRANOLOL; RAMELTEON; SEROTONIN AGONIST; SUMATRIPTAN; TEZAMPANEL; TONABERSAT; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROATE MAGNESIUM; VALPROATE SEMISODIUM; VALPROIC ACID;

ADD ON THERAPY; ADJUVANT THERAPY; CHEMOPROPHYLAXIS; CLINICAL EFFECTIVENESS; CLUSTER HEADACHE; DRUG EFFICACY; DRUG MISUSE; ELECTROSTIMULATION; EPISODIC MIGRAINE; FOCAL EPILEPSY; HEMICRANIA CONTINUA; HUMAN; LOW DRUG DOSE; MIGRAINE; MULTIPLE CYCLE TREATMENT; NERVE STIMULATION; NEURALGIA; NEUROMODULATION; OCCIPITAL NERVE STIMULATION; QUALITY OF LIFE; REFRACTORY CHRONIC MIGRAINE; REVIEW; SUNCT SYNDROME; TRANSFORMED MIGRAINE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANALGESICS; ANTICONVULSANTS; BOTULINUM TOXINS, TYPE A; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; MIGRAINE DISORDERS; RECEPTOR, MELATONIN, MT1; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; SEROTONIN RECEPTOR AGONISTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84865601065     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2012.709846     Document Type: Review

References (107)

1. Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache 2005;45:S3-13 (Pubitemid 40532985)
2. Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia 2011;31:301-15
3. Bigal ME, Sheftell FD, Rapoport AM, et al. Chronic daily headache: identification of factors associated with induction and transformation. Headache 2002;42:575-81
4. Silberstein SD, Lipton RB. Chronic daily headache. Curr Opin Neurol 2000;13:277-83 (Pubitemid 30406535)
5. Katsarava Z, Schneeweiss S, Kurth T, et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 2004;62:788-90 (Pubitemid 38298959)
6. Natoli J, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia 2010;30:599-609
7. Bigal ME, Serrano D, Reed M, et al. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 2008;71:559-66
8. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24:S9-160
9. Headache Classification Committee, Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006;26:742-6
10. Levin M. Refractory headache: classification and nomenclature. Headache 2008;48:783-90 (Pubitemid 351792750)
11. Schulman EA, Lake AE III, Goadsby P, et al. Defining refractory migraine and refractory chronic migraine: proposed criteria. Headache 2008;48:778-82
12. Robbins L. Refractory chronic migraine: long-term follow-up using a refractory rating scale. J Headache Pain 2012;13:225-9
13. Silberstein SD, Olesen J, Bousser MG, et al. International Headache Society. The International Classification of Headache Disorders, 2nd Edition (ICHD-II)-revision of criteria for 8.2 Medication-overuse headache. Cephalalgia 2005;25:460-5 (Pubitemid 40769867)
14. Allena M, Katsarava Z, Nappi G; COMOESTAS Consortium. From drug-induced headache to medication overuse headache. A short epidemiological review, with a focus on Latin American countries. J Headache Pain 2009;10:71-6
15. Rossi P, Jensen R, Nappi G, et al. COMOESTAS Consortium. A narrative review on the management of medication overuse headache: the steep road from experience to evidence. J Headache Pain 2009;10:407-17
16. Hagen K, Jensen R, Bøe MG, et al. Medication overuse headache: a critical review of end points in recent follow-up studies. J Headache Pain 2010;11:373-7
17. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343-9 (Pubitemid 46184209)
18. Antonaci F, Dumitrache C, De Cillis I, et al. A review of current European guidelines for migraine. J Headache Pain 2010;11:13-19
19. Schulman EA, Lee Peterlin B, Lake AE III, et al. Defining Refractory Migraine: results of the RHSIS Survey of American Headache Society Members. Headache 2009;49(4):509-18
20. Irimia P, Palma J-A, Fernandez-Torron R, Martinez-Vila E. Refractory migraine in a headache clinic population. BMC Neurol 2011;11:94
21. Diener HC, Dodick DW, Goadsby PJ, et al. Chronic migraine-classification, characteristics and treatment. Nat Rev Neurol 2012;14:8(3):162-71
22. Diener HC, Bussone G, Van Oene JC, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007;27(7):814-23 (Pubitemid 46961730)
23. Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007;47(2):170-80
24. Wheeler AH. Botulinum toxin A, adjunctive therapy for refractory headaches associated with pericranial muscle tension. Headache 1998;38:468-71 (Pubitemid 28399179)
25. Binder WJ, Brin MF, Blitzer A, et al. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg 2000;123:669-76
26. Barrientos N, Chana P. Botulinum toxin type A in prophylactic treatment of migraine headaches: a preliminary study. J Headache Pain 2003;4:146-51 (Pubitemid 38029031)
27. Shuhendler AJ, Lee S, Siu M, et al. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials. Pharmacotherapy 2009;29:784-91
28. Aurora SK, Gawel M, Brandes JL, et al. Botulinum toxin type A prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache 2007;47:486-99 (Pubitemid 46625251)
29. Silberstein SD, Gobel H, Jensen R, et al. Botulinum toxin type A in the prophylactic treatment of chronic tensiontype headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia 2006;26:790-800 (Pubitemid 43882987)
30. Padberg M, de Bruijn SF, de Haan RJ, et al. Treatment of chronic tension-type headache with botulinum toxin: a double-blind, placebo-controlled clinical trial. Cephalalgia 2004;24:675-80 (Pubitemid 39061258)
31. Schmitt WJ, Slowey E, Fravi N, et al. Effect of botulinum toxin A injections in the treatment of chronic tensiontype headache: a double-blind, placebo-controlled trial. Headache 2001;41:658-64 (Pubitemid 32777748)
32. Rozen D, Sharma J. Treatment of tension-type headache with botox: a review of the literature. Mt Sinai J Med 2006;73:493-8 (Pubitemid 43192236)
33. Naumann M, So Y, Argoff CE, et al. for the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70:1707-14 (Pubitemid 351644139)
34. Ondo WG, Vuong KD, Derman HS. Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. Cephalalgia 2004;24:60-5 (Pubitemid 38085196)
35. Mathew NT, Frishberg BM, Gawel M, et al. Botulinum toxin type A. BOTOX) for the prophylactic treatment of chronic daily headache: A randomized, doubleblind, placebo-controlled trial. Headache 2005;45:293-307 (Pubitemid 40530193)
36. Dodick DW, Mauskop A, Elkind AH, et al. Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 2005;45:315-24 (Pubitemid 40530195)
37. Mathew NT, Kailasam J, Meadors L. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache. Headache 2008;48:194-200 (Pubitemid 351178284)
38. Autret A, Valade D, Debiais S. Placebo and other psychological interactions in headache treatment. J Headache Pain 2012;13:191-8
39. Bendtsen L, Mattsson P, Zwart JA, et al. Placebo response in clinical randomized trials of analgesics in migraine. Cephalalgia 2003;23:487-90 (Pubitemid 37114968)
40. Loder E, Goldstein R, Biondi D. Placebo effects in oral triptan trials: the scientifi c and ethical rationale for continued use of placebo controls. Cephalalgia 2005;25:124-31 (Pubitemid 40193955)
41. Ashkenazi A, Silberstein S. Is botulinum toxin useful in treating headache? Yes. Curr Treat Options Neurol 2009;11:18-23
42. Evers S, Olesen J. Botulinum toxin in headache treatment: the end of the road?. Cephalalgia 2006;26:769-71 (Pubitemid 43882984)
43. Atȩ S Y. Botulinum toxin for the treatment of headaches: a review of current practices and evidence-based data. Agri 2006;18:5-11
44. Gupta VK. Botulinum toxin-a treatment for migraine? A systematic review. Pain Med 2006;7:3869-4
45. Pakalnis A, Couch J. Headache therapy with botulinum toxin-form over substance. Arch Neurol 2008;65:149-51
46. Roach ES. Questioning botulinum toxin for headache-reality or illusion. Arch Neurol 2008;65:151-2
47. Farinelli I, Coloprisco G, De Filippis S, et al. Long-term benefits of botulinum toxin type A (BOTOX) in chronic daily headache: a five-year long experience. J Headache Pain 2006;7:407-12 (Pubitemid 46085245)
48. Oterino A, Ramón C, Pascual J. Experience with onabotulinumtoxinA (BOTOX) in chronic refractory migraine: focus on severe attacks. J Headache Pain 2011;12:235-8
49. Bittar RG, Teddy PJ. Peripheral neuromodulation for pain. J Clin Neurosci 2009;16(10):1259-61
50. Weiner RL, Reed KL. Peripheral neurostimulation for control of intractable occipital neuralgia. Neuromodulation 1999;2(3):217-21 (Pubitemid 29409598)
51. Lambru G, Matharu MS. Occipital nerve stimulation in primary headache syndromes. Ther Adv Neurol Disord 2012;5(1):57-67
52. Ellens DJ, Levy RM. Peripheral neuromodulation for migraine headache. Prog Neurol Surg 2011;24:109-17
53. Jenkins B, Tepper SJ. Neurostimulation for Primary Headache Disorders, Part 1: pathophysiology and Anatomy, History of Neuromodulation in Headache Treatment, and Review of Peripheral Neuromodulation in Primary Headaches. Headache 2011;51(8):1254-66
54. Aurora SK, Dodick DW, Turkel CC, et al. PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010;30:793-803
55. Dodick DW, Turkel CC, DeGryse RE, et al. PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010;50:921-36
56. Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010;30:804-14
57. Lipton RB, Varon SF, Grosberg B, et al. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology 2011;77:1465-72
58. Mauskop A. The use of botulinum toxin in the treatment of headaches. Pain Physician 2004;7:377-87 (Pubitemid 39206377)
59. Olesen J, Tfelt-Hansen P. Licence for Botox in so-called chronic migraine. Lancet 2010;376:1825-6
60. Russell MB. Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine. J Headache Pain 2011;12:135-6
61. Gerwin R. Treatment of chronic migraine headache with onabotulinumtoxinA. Curr Pain Headache Rep 2011;15:336-8
62. Aurora S, Diener HC, Dodick D; PREEMPT Chronic Migraine Study Group. Reply: clinical trials on onabotulinumtoxinA for the treatment of chronic migraine. J Headache Pain 2011;12:137-8
63. Silberstein S, Tfelt-Hansen P, Dodick DW, et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia 2008;28:484-95 (Pubitemid 351502554)
64. Negro A, Martelletti P. Chronic migraine plus medication overuse headache: two entities or not?. J Headache Pain 2011;12:593-601
65. Blumenfeld A, Silberstein SD, Dodick DW, et al. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache 2010;50:1406-18
66. Blumenfeld AM, Schim JD, Chippendale TJ. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache 2008;48:210-20 (Pubitemid 351178286)
67. Magalhaes E, Menezes C, Cardeal M, et al. Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine. Clin Neurol Neurosurg 2010;112:463-6
68. Mathew NT, Jaffri SFA. A Double-Blind Comparison of OnabotulinumtoxinA (BOTOX) and Topiramate (TOPAMAX) for the Prophylactic Treatment of Chronic Migraine: A Pilot Study. Headache 2009;49:1466-78
69. Cady RK, Schreiber CP, Porter JA, et al. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache 2011;51:21-32
70. Saper JR, Dodick DW, Silberstein SD, et al. Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia 2011;31(3):271-85
71. Lipton R, Goadsby P, Cady R, et al. P047-PRISM study: occipital nerve stimulation for treatment-refractory migraine. Cephalalgia 2009;29(Suppl 1):1-166
72. Silberstein S, Dodick D, Saper J, et al. PSI-227. The safety and efficacy of occipital nerve stimulation for the management of chronic migraine. Cephalalgia 2011;31(Suppl 1):1-216
73. Aurora SK, Dodick DW, Turkel CC, et al.OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010;30(7):793-803
74. Cady R, Schreiber C. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Headache 2008;48:900-13 (Pubitemid 351795552)
75. Sandrini G, Perrotta A, Tassorelli C, et al. Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. J Headache Pain 2011;12:427-33
76. Eross EJ, Gladstone JP, Lewis S, et al. Duration of migraine is a predictor for response to botulinum toxin type A. Headache 2005;45:308-14 (Pubitemid 40530194)
77. Christie SN, Giammarco R, Gawel M, et al. Botulinum toxin type A and acute drug costs in migraine with triptan overuse. Can J Neurol Sci 2010;37:588-94
78. Goadsby PJ, Charbit AR, Andreou AP, et al. Neurobiology of migraine. Neuroscience 2009;161(2):327-41
79. Bartsch T, Goadsby PJ. Increased responses in trigeminocervical nociceptive neurons to cervical input after stimulation of the dura mater. Brain 2003;126(Pt 8):1801-13 (Pubitemid 36917339)
80. Bartsch T, Goadsby PJ. Stimulation of the greater occipital nerve induces increased central excitability of dural afferent input. Brain 2002;125(Pt 7):1496-509 (Pubitemid 34755165)
81. Goadsby PJ, Akerman S. The trigeminovascular system does not require a peripheral sensory input to be activated-migraine is a central disorder. Cephalalgia 2012;32:3-5
82. Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci 2011;12(10):570-84
83. Meehan AL, Yang X, McAdams BD, et al. A new mechanism for antiepileptic drug action: vesicular entry may mediate the effects of levetiracetam. J Neurophysiol 2011;106:1227-39
84. Beran RG, Spira PJ. Levetiracetam in chronic daily headache: a double-blind, randomised placebo-controlled study. (The Australian KEPPRA Headache Trial [AUS-KHT]). Cephalalgia 2011;31:530-6
85. Krüger S, Bräunig P. Intravenous valproic acid in the treatment of severe catatonia. J Neuropsychiatry Clin Neurosci 2001;13:303-4 (Pubitemid 32499683)
86. Afshari D, Rafizadeh S, Rezaei M. A comparative study of the effects of low-dose topiramate versus sodium valproate in migraine prophylaxis. Int J Neurosci 2012;122:60-8
87. Errington AC, Stohr T, Heers C, et al. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Neurofarmacology 2006;50:1016-29
88. Gutiérrez-Á lvarez AM, Sagarra-Mur D, Jiménez-Corral C. Lacosamide, new antiepileptic with broad perspectives. Neurologia 2011;26:568-9
89. Halasz P, Kälviainen R, Marzurkiewicz-Beldzinska M, et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 2009;50:443-53
90. Tfelt-Hansen PC, Olesen J. The 5-HT (1F) receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials. J Headache Pain 2012;13:271-5
91. Färkkilä M, Diener HC, Géraud G, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol 2012;11:405-13
92. Peroutka SJ. 2010: year in review. Headache 2011;51:181-7
93. Colman SS, Brod MI, Krishnamurthy A, et al.Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan. Clin Ther 2001;23:127-45 (Pubitemid 32113627)
94. Taylor FR. Migraine headache: options for acute treatment. Curr Neurol Neurosci Rep 2005;5:86-92
95. Yang ZY, Le Y, Hu TT, et al. Production of ultrafine sumatriptan succinate particles for pulmonary delivery. Pharm Res 2008;25:2012-18
96. Available from: www.optinose.com/clinical-trials/target-clinical-trial- formigraine
97. Frampton JE. Needle-free subcutaneous sumatriptan: in the acute treatment of migraine attacks or cluster headache episodes. CNS Drugs 2011;1;25:983-94
98. Negro A, Lionetto L, Simmaco M, et al. CGRP receptor antagonists: an expanding drug class for acute migraine?. Expert Opin Investig Drugs 2012;21:807-18
99. Coleman PJ, Schreier JD, Cox CD, et al. Discovery of [(2R,5R)-5-{[(5- Fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2- yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties. Chem Med Chem 2012;7:415-24
100. Available from: http://www.lupinworld. com/
101. Sang CN, Ramadan NM, Wallihan RG, et al. LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia 2004;24(7):596-602 (Pubitemid 39272960)
102. Stovner LJ, Tronvik E, Hagen K. New drugs for migraine. J Headache Pain 2009;10:395-406
103. Passie T. The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther 2008;14:295-314
104. Karst M, Halpern JH, Bernateck M, et al. The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: an open, non-randomized case series. Cephalalgia 2010;30:1140-4
105. Magis D, Bruno M-A, Fumal A, et al. Central modulation in cluster headache patients treated with occipital nerve stimulation: an FDG-PET study. BMC Neurol 2011;11:25
106. Dario A, Scamoni C, Peron S, Tomei G, et al. A case of post-traumatic cervicogenic headache treated by cervical cord stimulation. J Headache Pain; 2005;6:473 (Pubitemid 43078777)
107. Reed K, Black S, Banta C II, Will K. Combined occipital and supraorbital neurostimulation for the treatment of chronic migraine headaches: initial experience. Cephalalgia 2010;30:260-71